Key points are not available for this paper at this time.
Abstract Malic enzyme ( ME ) genes are key functional metabolic enzymes playing a crucial role in carcinogenesis. However, the detailed effects of ME gene expression on breast cancer progression remain unclear. Here, our results revealed ME1 expression was significantly upregulated in breast cancer, especially in patients with oestrogen receptor/progesterone receptor‐negative and human epidermal growth factor receptor 2‐positive breast cancer. Furthermore, upregulation of ME1 was significantly associated with more advanced pathological stages ( p < 0.001), pT stage ( p < 0.001) and tumour grade ( p < 0.001). Kaplan–Meier analysis revealed ME1 upregulation was associated with poor disease‐specific survival (DSS: p = 0.002) and disease‐free survival (DFS: p = 0.003). Multivariate Cox regression analysis revealed ME1 upregulation was significantly correlated with poor DSS (adjusted hazard ratio AHR = 1.65; 95% CI: 1.08–2.52; p = 0.021) and DFS (AHR, 1.57; 95% CI: 1.03–2.41; p = 0.038). Stratification analysis indicated ME1 upregulation was significantly associated with poor DSS ( p = 0.039) and DFS ( p = 0.038) in patients with non‐triple‐negative breast cancer (TNBC). However, ME1 expression did not affect the DSS of patients with TNBC. Biological function analysis revealed ME1 knockdown could significantly suppress the growth of breast cancer cells and influence its migration ability. Furthermore, the infiltration of immune cells was significantly reduced when they were co‐cultured with breast cancer cells with ME1 knockdown. In summary, ME1 plays an oncogenic role in the growth of breast cancer; it may serve as a potential biomarker of progression and constitute a therapeutic target in patients with breast cancer.
Hu et al. (Fri,) studied this question.